Activity

  • New research shows that B12 inhibits key enzyme activity in Parkinson’s Disease (LRRK2). Though this research is limited to cellular and animal models at this point, as Iban Ubarretxena pointed out this, “constitutes a huge step forward because it is a neuroprotective vitamin in animal models and has a mechanism unlike that of currently existing inhibitors. So it could be used as a basis to develop new therapies to combat hereditary Parkinson’s associated with pathogenic variants of the LRRK2 enzyme”.